Thoughts on Roche's G12C Update in Lung Cancer

研报英文原文证据摘录

Thoughts on Roche's G12C Update in Lung Cancer

Biotechnology - Oncology & Rare Diseases

Oncology - Market Overweight

ONCOLOGY July 8, 2026

The Wolfe Byte

Roche likely made the G12C inhibitor-naïve monotx lane harder for RVMD's eliron.

Best angle for others may be to lean into differentiation (e.g., post-OFF resistance Kalpit Patel

or a chemo-sparing 1L strategy); Upside/bull case in G12C lung for RVMD takes kpatel@wolferesearch.com

a modest hit. (646) 419-2570 View Kalpit’s Research

View Comp Table

Roche (RHHBY, not covered) recently hit PFS + OS endpoints in Krascendo 1, Gugan Raghuraman

a randomized head-to-head Phase III assessing divarasib vs. either sotorasib or graghuraman@wolferesearch.com646-419-2572

adagrasib in previously treated KRAS G12C NSCLC. While the full details remain

to unfold, we view the update as clearly negative for sotorasib/adagrasib and,

separately, as raising the bar for RVMD's (Outperform) elironrasib monotx path. The

door is not closed for RVMD in this indication, though we think the more defensible

path may be less about being “another better G12C inhibitor” in previously-tx pts,

and more about owning post-OFF-resistance biology or building a differentiated 1L

combo strategy.

We think the win is a big deal because it is not a squishy cross-trial comparison. The

primary endpoint was BICR-assessed PFS, with OS, ORR, DoR, and safety among

the secondary endpoints. We do not recall either sotorasib or adagrasib showing

an OS benefit in their historical randomized studies. Sotorasib’s CodeBreaK 200

showed a PFS benefit vs. docetaxel but did not meet the secondary OS endpoint,

while adagrasib’s KRYSTAL-12 was also primarily framed around a PFS/ORR win vs.

docetaxel.

This directly pressures eliron monotx. RVMD's data have been encouraging